搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
2 天
on MSN
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.
每日经济新闻 on MSN
18 小时
九洲药业:公司服务客户包括 Novartis、Roche、Zoetis、Gilead等国际知名 ...
每经AI快讯,有投资者在投资者互动平台提问:请问吉利德是否为公司重要客户?有提供了哪些产品和服务吗?谢谢 九洲药业(603456.SH)9月20日在投资者互动平台表示,公司服务客户包括 ...
2 天
on MSN
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...
biopharma-reporter
1 天
Novartis’ Kisqali receives FDA approval to reduce the risk of breast cancer recurrence
Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...
2 天
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability ...
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...
Pharmabiz
20 小时
New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch ...
New Novartis data in relapsing MS reinforce benefits of Kesimpta for first-line and switch patients: Basel Friday, September 20, 2024, 12:00 Hrs [IST] Novartis announced new data ...
2 天
Novartis AG: Hold Rating Justified Amid Kisqali’s Market Potential and FDA Approval
Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report) and keeping the price ...
9 天
Novartis股票面临Kisqali专利诉讼的尾部风险 - 美银证券
周三,美银证券调整了对Novartis (NOVN:SW) (NYSE: NVS)股票的立场,将这家制药巨头的评级从买入下调至中性。该公司还修改了Novartis的目标价,将其从之前的110.00瑞士法郎下调至110.00瑞士法郎。这一评级变化是在Novartis相对于其欧洲制药同行表现出色之后做出的。 自2023年初以来,Novartis因一系列成功的III期试验和持续超出预期的盈利而备受关注, ...
4 天
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.
STAT
3 天
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
FiercePharma
3 天
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...
SHINE
4 天
Joerg Reinhardt: Shanghai has the talent and the technology to find innovative solutions to ...
Joerg Reinhardt, Chairman of the Board of Directors of Novartis AG, envisions Shanghai in the next decade.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈